In the race to find a vaccine that protects from COVID 19, an important step has just been taken: a Phase I clinical trial in humans has just started with the injection into a first volunteer of mRNA-1273 from the American biotech Moderna.
The clinical trial was organized with the NIH (National Institute of Health, American equivalent of Inserm). It takes place in Seattle and will include 45 adults aged 18 to 55. The objective is to verify the safety and immunogenicity (ability to trigger an immune reaction) of the product. Three dosages will be tested according to a vaccination schedule which provides for the administration of two doses four weeks apart.
–
Related posts:
Brazil's "loneliest male in the planet" dies
China has canceled thousands of flights and disrupted rail traffic - social network
In August, more foreign guests were registered in tourist accommodation establishments than in July
The last chance to escape, Ukraine was unable to stop a massive Russian advance on Pokrovsk
